Vor Bio Appoints David Zaccardelli to Board of Directors
Vor Bio appointed David Zaccardelli to its Board of Directors, replacing outgoing director Andrew Levin of RA Capital Management. Dr. Zaccardelli brings significant commercial experience, having led Verona Pharma through its $10 billion acquisition by Merck and previously serving as CEO of Dova Pharmaceuticals.
Key figures
- Drug Name
- Telitacicept
- Phase Of Trial
- Phase 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.